Keystone Law corporate partner Catherine Williams and intellectual property partner Maureen Kelly have advised PrecisionLife, the biotechnology company, on the acquisition of intellectual property from GenoKey ApS, the Danish genomic analytics firm.

The transaction will bring together the leaders in combinatorial analytics and large-scale genomic analysis and enable PrecisionLife to continue its expansion as an AI-enabled precision medicine company.

PrecisionLife’s platform, which includes technology developed with GenoKey, enables the company to gain unique insights into genes associated with disease, as biomarkers and as targets for drug discovery. PrecisionLife’s business model maximises the impact of its platform by partnering with others as well as building a pipeline of proprietary assets in chronic diseases.

Dr Steve Gardner, CEO of PrecisionLife, said:

“Catherine and Maureen’s guidance throughout our transaction has been instrumental in solidifying our long-term partnership with GenoKey. Their expert support and strategic insights are perfectly complemented by Maureen’s deep understanding of the life sciences sector and our business, which helped to make the whole process seamless. We look forward to working with them again in the future.”

Commenting on the acquisition, Catherine Williams added:

“This is a significant transaction for PrecisionLife and presents an exciting opportunity for the company to develop new solutions for patients with chronic diseases. Maureen and I were delighted to assist PrecisionLife.”